Nephrotect otopina za infuziju
| Name | Nephrotect otopina za infuziju |
|---|---|
| Marketing Authorisation Number | HR-H-058269986 |
| Active Substance | izoleucin leucin lizinacetat metionin fenilalanin treonin triptofan valin arginin histidin alanin acetilcistein glicin prolin serin tirozin glicil-tirozin |
| Composition | 1000 ml otopine za infuziju sadrži: 5,80 g izoleucina, 12,80 g leucina, 16,90 g lizin acetata (12,0 g lizina), 2,00 g metionina, 3,50 g fenilalanina, 8,20 g treonina, 3,00 g triptofana, 8,70 g valina, 8,20 g arginina, 9,80 g histidina, 6,20 g alanina, 0,54 g acetil cisteina (0,40 g cisteina), 5,31 g glicina, 3,00 g prolina, 7,60 g serina, 0,60 g tirozina i 3,16 g glicin-tirozina (0,994 g glicina i 2,40 g tirozina); ukupno 100 g/l aminokiselina, odnosno 16,3 g/l dušika |
| Pharmaceutical Form | otopina za infuziju |
| Manufacturer | Fresenius Kabi Austria GmbH, Graz, Austrija |
| Marketing Authorisation Holder | Fresenius Kabi d.o.o., Radnička cesta 37a, Zagreb, Hrvatska |
| Marketing Authorisation Date | 28.07.2020 |
| MA Period of Validity | unlimited |
| MA Revocation Date | 09.06.2025* |
| Classification Number | UP/I-530-09/17-02/717 |
| Registration Number | 381-12-01/154-20-04 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | Medicinal product subject to restricted medical prescription |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | B05BA01 |
| Marketing status | Not marketed |
| SmPC | download |
| PL | download |
*Note
Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act, only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.